Breast Cancer Diagnostics Market to Reach USD 8,738.9 Million By 2027 | Reports And Data
25 nov. 2020 11h50 HE
|
Reports and Data
New York, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Growing awareness for early detection of breast cancer is one of the significant factors influencing the market growth. Market Size – USD 4,955.1 Million...
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
15 mai 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...
Bionano Genomics Launches New Capabilities of the Saphyr System to Significantly Increase Its Cost Effectiveness, Speed and Ease of Use for Whole Human Genome Structural Variation Analysis and Digital Cytogenetics
01 mars 2019 08h00 HE
|
Bionano Genomics
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...
Bionano Genomics’ Saphyr® System Used for Highly Accurate Detection of the Genetic Disorder FSHD as an Alternative to Southern Blot
06 févr. 2019 08h00 HE
|
Bionano Genomics
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...
Global Adoption of Bionano Genomics’ Saphyr® System Accelerating for Clinical Genomics Applications
14 janv. 2019 08h00 HE
|
Bionano Genomics
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr system, which enables ultra-sensitive...
UPDATE – GrandOmics Biosciences Offers Genetic Test Using the Saphyr System for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) in China
19 oct. 2018 20h51 HE
|
Bionano Genomics; GrandOmics Biosciences
SAN DIEGO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...
Bionano and Genoox Launch Integrated Platform for Identification of Structural Variants in DNA
17 oct. 2018 11h00 HE
|
Bionano Genomics
SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...
Bionano Genome Mapping Found to Be Superior to Existing Clinical Tests for the Identification of Pathogenic Structural Variants in Duchenne Muscular Dystrophy
01 nov. 2017 08h00 HE
|
Bionano Genomics
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- In a publication in Genome Medicine, a team of researchers from Children’s National Health Center (CNHC) and the University of California, Los Angeles...
Beijing Grandomics Announces Intent to Use the Saphyr System for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) in China
19 oct. 2017 14h00 HE
|
Bionano Genomics
BEIJING and ORLANDO, Fla., Oct. 19, 2017 (GLOBE NEWSWIRE) -- At the 2017 annual meeting of the American Society of Human Genetics in Orlando, Depeng Wang, the Chief Executive Officer of Beijing...
Genoptix and Bionano Genomics Announce Strategic Alliance
28 juin 2017 08h00 HE
|
BioNano Genomics; Genoptix, Inc.
SAN DIEGO and CARLSBAD, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Genoptix, Inc., a leading oncology diagnostics and informatics company, and Bionano Genomics®, Inc., a company focused on genome...